Vaginitis: Review on Drug Resistance

Author(s): Graziela Vargas Rigo, Tiana Tasca*

Journal Name: Current Drug Targets

Volume 21 , Issue 16 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Female genital tract infections have a high incidence among different age groups and represent an important impact on public health. Among them, vaginitis refers to inflammation of the vulva and/or vagina due to the presence of pathogens that cause trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis. Several discomforts are associated with these infections, as well as pregnancy complications and the facilitation of HIV transmission and acquisition. The increasing resistance of microorganisms to drugs used in therapy is remarkable, since women report the recurrence of these infections and associated comorbidities. Different resistant mechanisms already described for the drugs used in the therapy against Trichomonas vaginalis, Candida spp., and Gardnerella vaginalis, as well as aspects related to pathogenesis and treatment, are discussed in this review. This study aims to contribute to drug design, avoiding therapy ineffectiveness due to drug resistance. Effective alternative therapies to treat vaginitis will reduce the recurrence of infections and, consequently, the high costs generated in the health system, improving women’s well-being.

Keywords: Vaginitis, drug target, resistance, Trichomonas vaginalis, Gardnerella vaginalis, Candida spp.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 14 December, 2020
Page: [1672 - 1686]
Pages: 15
DOI: 10.2174/1389450121666200804112340
Price: $65

Article Metrics

PDF: 34